Analysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $68.67

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $68.6667.

A number of analysts have weighed in on the stock. Guggenheim reduced their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. HC Wainwright decreased their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Finally, Lifesci Capital raised Structure Therapeutics to a “strong-buy” rating in a report on Monday, September 8th.

Structure Therapeutics Trading Up 0.4%

Structure Therapeutics stock opened at $30.19 on Friday. The business’s fifty day simple moving average is $22.01 and its two-hundred day simple moving average is $21.32. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $42.57. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -28.75 and a beta of -1.65.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, equities research analysts predict that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wyoming bought a new stake in shares of Structure Therapeutics in the second quarter worth approximately $28,000. Assetmark Inc. boosted its holdings in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after purchasing an additional 820 shares during the last quarter. National Bank of Canada FI grew its position in Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock worth $51,000 after purchasing an additional 2,766 shares during the period. ANTIPODES PARTNERS Ltd raised its stake in Structure Therapeutics by 310.7% during the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock valued at $74,000 after buying an additional 3,213 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after buying an additional 994 shares during the period. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.